The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

A quick finger prick and a few drops of blood on a card that can be sent in regular mail—This approach could soon make ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

For now, after obtaining approval for early stages of cognitive decline and dementia, lecanemab and donanemab continue their ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Six years after his Alzheimer’s diagnosis, 90-year-old Zelik Bocknek (Zel) refuses to slow down — and he believes his active ...

In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...